Portal de Periódicos da CAPES

PROPHYLACTIC IMMUNOSUPPRESSION WITH ANTI-INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY LO-TACT-1 VERSUS OKT3 IN LIVER ALLOGRAFTING

1996; Wolters Kluwer; Volume: 61; Issue: 9 Linguagem: Inglês

10.1097/00007890-199605150-00022

1534-6080

Raymond Reding, Axel Feyaerts, H. Vraux, Dominique Latinne, Bernardo De La Parra, Anne Cornet, Fran oise Cormont, Jacques Jamart, Étienne Sokal, Jean de Ville de Goyet, Jan Lerut, Herv Bazin, Jean-Bernard Otté,

Cytomegalovirus and herpesvirus research

A prospective trial was conducted in 129 recipients of primary liver transplantation, to compare induction immunosuppression using triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n=42), versus triple drug therapy with a 10-day course of OKT3 (group 2, n=44) or of the anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n=43). Two-year actual patient survival rates were 64%, 79%, and 93% in groups 1, 2, and 3, respectively (1 vs. 2, NS; I vs. III, P=0.003; 2 vs. 3, NS). Up to 2 years after transplantation, 18%, 44%, and 53% of the grafts in groups 1, 2, and 3, respectively, had not experienced steroid-resistant acute rejection (1 vs. 2, P=0.002; 1 vs. 3, P=0.007; 2 vs. 3, NS). The overall incidence of chronic rejection was 4%. OKT3 therapy, but not LO-Tact-1, significantly increased the incidence of cytomegalovirus infections (P=0.019). In conclusion, immunoprophylaxis with LO-Tact-1 seemed to provide a liver graft acceptance rate at least as satisfactory as that with OKT3, without an increase in the incidence of infections.